Lipogen Targets US Brain Health Market
All-natural Lipogen PS has been clinically tested in a double-blind, placebo-controlled studies that showed significant memory and mental improvements in comparison to the placebo groups.
20/02/07 Lipogen, Israel, increases production capacity in order to supply the growing demand for their Lipogen PS (phosphatidylserine) – a patented product line for the food and beverage fortification market and the dietary supplement market in the USA.
The state-of-the-art facility in the North of Israel has completed installation of production facilities to ensure supplying Lipogen PS. This move has increased the production capacity by 100%.
“Following the FDA GRAS affirmation in 2006, we expect to increase our sales growth in the market in about 50% during 2007,” explains David Rutenberg, CEO at Lipogen. “The expansion of the production facility enables us to cut down PS cost production. Lipogen intends to penetrate the US functional foods market and achieve a significant market share. We decided to adjust our pricing structure to match the conventional rates of the functional food market. Lipogen's new prices will be implemented also in the dietary supplements market, so that both segments will benefit from this strategic move. Lipogen's mission is to help children and adults alike to improve their brain health.”
All-natural Lipogen PS has been clinically tested in a double-blind, placebo-controlled studies that showed significant memory and mental improvements in comparison to the placebo groups. This improvement can be attributed to the use of phosphatidylserine, which is mostly found in brain cells and is involved in numerous functions of neuronal activity.
“This is the first step in implementing our strategy to maintain our leading position in the market for high-value natural PS. The US market is looking for innovative functional food solutions and is ready to use this exciting brain health ingredient in several food categories,” adds Rutenberg.
